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System performance evaluation of the cobas t 711 and cobas
t 511 coagulation analyzers in routine laboratory settings
Steve Kitchena, Moniek de Maatb, Michael Naglerc, Robert Jonesa,
Anna Lowea, John Burdend, Kai Gronebergd and Gergely Rozsnyaid
Utility of coagulation analyzers in real-world settings
depends on characteristics that are often not studied
comprehensively. This study aimed to investigate the
analytical performance, system functionality, practicability,
consistency and throughput of two new automated
coagulation analyzers in routine laboratory practice. Real-
world settings were simulated in three major European
hemostasis laboratories and multiple assays were
performed in anonymized plasma samples in parallel with
routine clinical practice on the cobas t 711 (high-
throughput) and cobas t 511 (mid-throughput) analyzers
using activated partial thromboplastin time (aPTT), aPTT
Lupus, aPTT Screen, Antithrombin (AT), D-Dimer,
Fibrinogen, Prothrombin Time (PT)-derived Fibrinogen, PT
Owren, PT Rec (recombinant human thromboplastin
reagent) and Thrombin Time assays. Precision was tested in
a 21-day experiment and accuracy was compared with
reference methods of the same laboratory. A number of
experiments simulated challenging real-life situations.
Pearson’s correlation coefficient was more than 0.98 in all
assays. Across assays, coefficients of variation ranged from
0.0 to 1.5% for intermediate precision; 0.2 to 3.0% for
repeatability and 0.4 to 3.7% for total precision. Good
between-run comparability was seen when testing samples
under random conditions. Calculated maximum throughput
was 197 and 387–402 tests/h for the cobas t 511 and 711
analyzers, respectively. Practicability met or exceeded user
expectations in 98% of cases. In a simulated real-life setting
of three major laboratories, the new cobas t 511 and cobas t
711 coagulation analyzers demonstrated a good
functionality, practicability and performance and the
throughput was high. Blood Coagul Fibrinolysis 31:459–468
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Introduction
Coagulopathies comprise a broad group of hemostatic
disorders with various causes ranging from congenital to
trauma and pharmacotherapy related. Coagulopathies
share a common risk of serious and life-threatening
episodes of bleeding or thrombosis contributing to sig-
nificant morbidity and mortality [1–7]. Coagulation tests
are used widely in clinical practice for the screening,
diagnosis and assessment of coagulopathies, and also for
the therapeutic drug monitoring of anticoagulant thera-
pies [8–12]. Key parameters include prothrombin time
(PT), activated partial thromboplastin time (aPTT),
thrombin time (TT), fibrinogen and D-Dimer [13–23].
Indicators of the hemostatic function need to be accu-
rately, reliably and quickly measured to assist clinical
diagnosis and treatment of coagulation abnormalities
[24,25]. The availability of new-generation, fully auto-
mated, high-throughput coagulation analyzers offers
potential benefits toward meeting clinical need and
increasing accuracy while reducing errors [26].
The cobas t 711 and cobas t 511 analyzers (Roche Diag-
nostics GmbH, Switzerland) are new-generation, fully
automated coagulation analyzers. Both analyzers utilize
reagent cassettes offering automatic reconstitution of
lyophilized reagents, which is designed to maximize auto-
mation and programmability. The potential advantages
include increased precision and accuracy compared with
pipetting when manually reconstituting reagents,
increased walkaway time for operators and efficiencies
in scheduling sample runs [26]. Assays used for routine
coagulation testing with the cobas t 711 and 511 analyzers
include three different aPTT reagents (aPTT, aPTT
Lupus, aPTT Screen), AT, D-Dimer, Fibrinogen, PT-
derived Fibrinogen, PT Owren and PT Rec (recombinant
human thromboplastin reagent); their analytical perfor-
mance has been described in detail previously [26–29].
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The cobas t 711 and 511 analyzers are built on identical
technology and operating methodology, and differ only in
capacity and throughput, with the cobas t 711 a high-
throughput analyzer capable of running a maximum of
390 tests/h, and the cobas t 511 a mid-throughput analyzer
capable of running 195 tests/h. In addition, the cobas t 711
analyzer can be directly connected to laboratory automa-
tion and information technology systems, forming part of
integrated laboratory solutions.
While the analytical performance of the cobas t 711 and
cobas t 511 analyzers and the associated assays have been
demonstrated in controlled conditions, the applicability
of the system in real-world settings has not yet been
described. Determining the practicability, functionality,
throughput and consistency of analytic instruments is
vital to guide laboratory managers on their use. This
multicenter study aimed to evaluate the analytical per-
formance, functionality and reliability of the cobas t 711
and cobas t 511 analyzers under simulated routine-like
‘intended-use’ laboratory conditions.
Materials and methods
Study design
The study was conducted between January 2017 and April
2017 at three European teaching hospitals (Inselspital
University Hospital, Bern, Switzerland; Erasmus Univer-
sity Medical Center, Rotterdam, The Netherlands; Shef-
field Haemostasis and Thrombosis Centre, UK).
Anonymized residual sodium citrate (3.2%/0.109 mol/l)
plasma samples were evaluated on the cobas t 711
(high-throughput; max. 390 tests/h: all three centers)
and cobas t 511 (mid-throughput; max. 195 tests/h: UK
center only) analyzers, using a number of coagulation
assays (aPTT, aPTT Lupus, aPTT Screen, AT, D-Dimer,
Fibrinogen, PT-derived Fibrinogen, PT Owren, PT Rec
and TT; Roche Diagnostics, Switzerland) described in
detail previously [27,29]. All assays and analyzers were
used according to manufacturers’ instructions.
Independent ethics committee approval was obtained
before study initiation and the study was performed
according to the principles of the Declaration of Helsinki
and International Council for Harmonisation Good Clin-
ical Practice guidelines.
Reproducibility and quality control
A 5-day interlaboratory reduced scope reproducibility
survey was conducted using control material to confirm
comparable recovery levels between the three sites.
Quality control was performed daily throughout the study
prior to running experimental samples to ensure com-
pleteness, correctness, plausibility and validation of read-
ings. Dependent on the assay, two to three quality control
levels were used with an acceptability cutoff of 2 SDs
of defined analyte recovery target range, as per routine
laboratory practice.
Intermediate precision
Intermediate precision – within-laboratory, day-to-day
precision – was assessed as analytic performance over 21
days according to Clinical Laboratory Standards Institute
(CLSI) EP05-A3 guidelines. Quality control target value
recovery was assessed in selected control material. Two
runs daily of each quality control material were con-
ducted, with at least two quality control samples per test
using the coagulation assays described above (84 mea-
surements per material-test combination). Over the 21
days, each control sample measurement was performed
with all parameters from the same sample, to better
simulate routine conditions. Acceptance criteria included
system behavior as expected (i.e. processing, loading and
unloading without problems); sample handling as
expected (i.e. loading and unloading of sample racks,
handling of sample containers, all results available on
graphical user interface and uploaded to WinCAEv); and
coefficient of variances according to industry-standard
test-specific criteria for intermediate precision (Table
S1; Supplementary Materials, http://links.lww.com/
BCF/A72).
System precision
Precision – agreement between-run and within-labora-
tory series – was also assessed in several runs of a routine
simulation precision (RSP) experiment that tested for
systematic or random errors that may occur during ‘real-
life’ routine use by comparing recovery and imprecision
during randomized processing. This test was designed to
partially reflect sampling and testing sequences in each
laboratory, with that produced during batch analysis [30].
Reference runs using all 10 assays and the same request
panel from each sample (15 measurements) were fol-
lowed by a random part where the same samples were
tested, but both the sample order and the test requests
were randomized and spiked with provocations (e.g.
insufficient sample or reagent) to challenge the function-
ality of the analyzer (7–47 measurements depending on
test, to represent routine testing patterns). Acceptability
criteria included no random or systematic errors detected;
reproducibility during random part comparable with ref-
erence part; and system handling provoked variability
being within specification.
System consistency
Consistency – agreement in changing and challenging
situations – was assessed over several runs of a routine
simulation series (RSS) experiment that confirmed the
absence of random errors when running each analyzer
under simulated routine conditions [31]. The experiment
consisted of the routine simulation download (RSD) test
described below, followed by immediately running the
same samples in the same sequence representing various
sample concentrations over the analytical range. Results
5% were considered acceptable with no further analysis
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required, while findings more than 5% required careful
assessment to identify route of deviation.
System throughput
Throughput was assessed in the RSD experiment that
replicated routine laboratory workflows and determined
the throughput of machines under ‘real-world’ usage.
This experiment evaluated the same test request pattern
and workload under seven different scenarios. The
detailed scenarios and outcomes for the RSD are shown
in Table S2 (Supplementary Materials, http://links.lww.
com/BCF/A72). Briefly scenarios A1–3 and B determined
the time required for all sample measurements per-
formed on the cobas t 711 or cobas t 511 analyzers,
according to various special conditions (e.g. quality con-
trol status time out on every application, optimization of
rack release times etc.); scenario C added automatic
hemolysis, icterus, lipemia (HIL) testing; scenario D
included provocations (e.g. foamy, clotted or closed sam-
ple tubes with pressure errors) performed to enable
reporting on machine performance under stress; and
scenario E determined walkaway time (i.e. time the
analyzer can run unattended) with the maximum number
of samples.
System practicability
Practicability and usability were assessed via a user
questionnaire. Operators were asked to rate both the
cobas t 711 analyzer and their routine laboratory analyzer
(score 1–10) for the following domains: general, general
aspects of software, processing of samples, test reagents,
calibration, quality control and maintenance. The fea-
tures of each domain are shown in Table S3 (Supplemen-
tary Materials, http://links.lww.com/BCF/A72).
Data analysis
All assay output was directly captured, statistically ana-
lyzed and archived by WinCAEv, a Code of Federal
Regulations Title 21 Part 11-compliant electronic data
capture and statistical analysis software developed and
validated for Roche-sponsored studies [30]. Where pos-
sible, discordant values and unexpected hardware or
software behavior were assessed to determine if samples
or experiments should be rerun. Outliers that could not
be omitted due to clearly identified and documented
errors (e.g. transcription, calculation errors etc.) were
included in statistical analyses. System-related outliers
were always included in the statistical analysis set, with
elucidating information on the root cause added.
The coefficient of variance was calculated for repeatabil-
ity and intermediate/total precision and compared against
prespecified acceptance ranges (Table S1; Supplemen-
tary Materials, http://links.lww.com/BCF/A72). For AT
only, SD was calculated at less than 80% activity as it was
defined at a level that was still accurate at the medical
decision point of 70–80%, where coefficient of variance
would be too great. Coefficient of variances and analyte
recoveries were calculated for RSP experiments, with an
acceptance criterion of CVrandom 1.5CVbatch. Poten-
tial system malfunction was defined by an analyte recov-
ery per aliquot during random part more than 10% of the
batch mean. In RSD experiments, measured average
throughput, calculated maximum throughput and
median sample processing time were calculated. For
RSS, slope and intercept were calculated according to
Passing–Bablok regression analyses and Pearson’s r cor-
relation coefficient was estimated; proportion of recover-
ies in the following ranges were reported: 5, þ5–10, 5–
10, þ10–15, 10–15%, more than þ15%, more than
15%. Measures of practicability derived from operator
questionnaire results were expressed as average score
weighted based on responder-reported importance
(weighted averages).
Results
Intermediate precision
Analytical performance of the cobas t 711 and cobas t 511
analyzers for the 10 coagulation assays studied in the 21-
day precision analysis are presented in Table 1. All values
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Table 1 Analytical performance of the cobas t 711 and cobas t 511 analyzers for each coagulation assay (21-day precision)
Intermediate precision (% CV) Repeatability (% CV) Total precision (% CV)
Assaya cobas t 711b cobas t 511c cobas t 711b cobas t 511c cobas t 711b cobas t 511c Acceptance criteria (%)
aPTT 0.0–0.5 0.2–0.3 0.2–0.4 0.3–0.4 0.4–0.7 0.4–0.6 5.0
aPTT Lupus 0.1–0.7 0.4–0.6 0.3–0.6 0.4–0.5 0.6–1.4 0.8–1.3 5.0
aPTT Screen 0.0–0.6 0.0–0.3 0.3–0.9 0.6–1.0 0.5–1.3 1.0–1.3 5.0
Antithrombin 0.0–1.9 0.9–1.4 1.3–1.8 0.9–1.0 1.0–2.7 1.4–2.2 5.0
D-Dimer 0.0–0.0
0.0–0.0
0.6
1.0
1.4–1.5
0.6–1.5
1.5
0.9
1.5–2.7
1.0–2.0
2.4
2.0
6.0
4.0
Fibrinogen 0.0–1.5 0.0–1.0 1.2–3.0 1.7–2.6 1.8–3.6 2.0–3.7 5.0
PT-derived Fibrinogen 0.0–0.0 0.8 1.5–2.5 2.1 2.3–2.9 2.2 7.0
PT Owrend 0.0–0.9 0.6–1.3 0.4–1.3 0.7–0.9 1.0–2.2 1.8–2.2 5.0
PT Recd 0.0–0.6 0.0–0.4 0.3–1.1 0.3–0.5 0.5–1.8 0.6–1.8 5.0
Thrombin Time 0.6–0.9
0.0–1.2
0.9
0.7
1.0–2.0
1.1–2.3
1.1
1.4
1.5–2.1
1.9–2.5
1.6
1.8
5.0
8.0
aPTT, activated partial thromboplastin time; CV, coefficient of variation; INR, international normalized ratio; PT, prothrombin time; Rec, recombinant human thromboplastin
reagent. a Results for control samples with the same acceptance criteria are pooled, and results for control samples with different acceptance criteria are presented
separately (D-dimer and thrombin time). b cobas t 711 analyzer tested at three sites. c cobas t 511 analyzer tested at one site. d Both INR and time units summarized.
were within the prespecified acceptance criteria (Table
1). Across assays, coefficient of variances for intermediate
precision ranged from 0.0 to 1.5% on the cobas t 711
analyzer, and from 0.0 to 1.3% on the cobas t 511 analyzer;
coefficient of variances for repeatability ranged from
0.2 to 3.0% on the cobas t 711 analyzer, and from
0.3 to 2.6% on the cobas t 511 analyzer; and coefficient
of variances for total precision ranged from 0.4 to 3.6% on
the cobas t 711 analyzer, and from 0.4 to 3.7% on the
cobas t 511 analyzer.
System precision
Up to six RSP runs were performed in each laboratory in
the RSP experiment: site 1 cobas t 711 analyzer, 3 runs/
1500 samples/5000 measurements; site 2 cobas t 711
analyzer, 3 runs/700 samples/3500 measurements; site
3 cobas t 511 analyzer, 2 runs/330 samples/1500
measurements; site 3 cobas t 711 analyzer, 4 runs/
1500 samples/5000 measurements.
Across centers, imprecision was less than 1% for the
majority of assays, with all batch and random part results
within the allowed ranges (within-run precision and
intermediate precision limits, respectively). Overall per-
formance for random part coefficient of variances never
exceeded the intermediate precision specifications
(Fig. 1). Minor variation between sites, with more fre-
quently seen imprecision in site 3, was attributed by
investigator to the use of older samples (up to 48 h).
Where CVrandom exceeded CVbatch by greater than 1.5
times, coefficient of variances were always within the
predefined specification for intermediate precision. All
recovery levels during the random part of the analysis
(simulating systematic or random errors occurring during
routine use) were within a 10% range (Fig. 2a–d).
In ‘routine-like’ conditions, the measured average
throughput for the cobas t 511 analyzer was 124 tests/
h, and for the cobas t 711 analyzer, 303–340 tests/h. The
calculated maximum throughput was 197 tests/h for the
cobas t 511 analyzer compared with 387–402 tests/h for
the cobas t 711 analyzer.
System consistency
In the RSS experiment, good between-run comparability
was seen when testing single samples under random
mode conditions (N¼ 1370 samples: site 1 cobas t 711
analyzer, n¼ 650; site 2 cobas t 711 analyzer, n¼ 280; site
3 cobas t 511 analyzer, n¼ 240; site 3 cobas t 711 analyzer,
n¼ 200). Results from the Passing–Bablok regression
analyses are shown in Table 2, with site-specific correla-
tion graphs in Figs. S1–S4 (Supplementary Materials,
http://links.lww.com/BCF/A72).
The vast majority (95%) of the 3180 measurements
conducted across the three sites met the acceptance
criteria of 5% of expected result. The distribution of
scores was narrow in this analysis, with 3.2 and 1.1% of
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Analytical recovery of assays run on cobas t 711 and cobas t 511 analyzers at: (a) site 1 (cobas t 711), (b) site 2 (cobas t 711), (c) site 3 (cobas t 711)
and (d) site 3 (cobas t 511). Representative data from a single run showing mean analytical recovery for the 10 assays observed during the routine
simulation precision experiment. Relative recovery of each assay in the batch mode (same test request pattern of each sample, defined order of samples)
is shown to the left of the black dividing line, relative recovery is shown to the right of the dividing line, when sample order and test requests were
randomized and spiked with provocations to highlight any possible random or systematic errors. aPTT, activated partial thromboplastin time; AT,
antithrombin; D-DI, D-dimer; FIBR, fibrinogen; HSP, human sample pool; PT, prothrombin time; Rec, recombinant human thromboplastin reagent.
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(Continued).
samples falling into less than –5% and more than 5%
categories, respectively, and less than 1% of samples
falling into other categories. Investigator-reported expla-
nations for results in the more than 5% categories
included age of samples (>24–48 h) and precision of
assays. No system malfunctions were observed.
System throughput
In the RSD experiment, each laboratory used their own
daily routine’s workload from a typical day and tested the
same test request pattern and workload under different
conditions for each scenario. The results were broadly
comparable between centers (Table S4; Supplementary
Materials, http://links.lww.com/BCF/A72). Of note, the
addition of HIL testing in scenario C impacted both
throughput and the time the racks spent on the instru-
ment (from around 10 min without HIL vs. up to 38 min
with HIL). Similar outcomes were observed in scenario B
when replacing PT Rec with PT Owren (around 10 vs.
38 min). The maximum walkaway time measured with
continuous-feed rack on the cobas t 711 analyzer was 4 h
42 min compared with 1 h 1 min on the cobas t 511
analyzer with manual rack loading. The measured
throughput of the cobas t 711 instruments varied between
90 and 273 tests/h, with a calculated throughput of around
200–400 tests/h. For the cobas t 511 instrument the
measured throughput was 120–150 tests/h and the calcu-
lated throughput was 168–189 tests/h. All provocations
were handled by the operators without difficulty and did
not cause disruption to the routine. All the erroneous
samples were correctly identified via alarm messages.
System practicability
Weighted average ratings by domain from the operator-
completed practicability questionnaire are presented in
Fig. 3. Based on the responses, 98% (898/915) of all
questions were graded as met or exceeded expectation.
Among areas where operators were less satisfied, these
could be explained by the age of samples used in the
study (e.g. >24 h causing closed sample tube pipetting
issues), which would not be seen in standard laboratory
practice, or easily addressable through planned software
updates (e.g. prominence of alarms and notifications).
Discussion
The current study assessed analytical performance, func-
tionality and reliability of the cobas t 711 and cobas t 511
coagulation analyzers under simulated routine laboratory
conditions. Observed analytical performance was excel-
lent, with coefficient of variances for repeatability of 3.0%
or less and coefficient of variances for intermediate
precision and total precision of 1.5 and 3.7% or less,
respectively. Despite their increasing use, sigma scores
were not calculated in the current study. Instead, we used
reference specifications from the cobas t 711 assays’
multicenter evaluation studies, where precision and accu-
racy assessments follow CLSI guidelines, and do not
prescribe the use of sigma metrics. Furthermore, recent
evidence questions the utility of the six-sigma method for
assessing hemostatic assay performance [32]. For this
reason we followed statistical methods outlined in the
respective CLSI guidelines and have presented descrip-
tive parameters of variation. The acceptance criterion
used in this analysis was an upper percentage limit, and
observed values were consistent with investigator expec-
tations and data from similar analyzers. No systematic or
random errors were detected in the system precision
(RSP experiment) analysis. Imprecision was less than
1% for the majority of assays used and recovery levels
were within acceptance criteria. In the RSD test, both
analyzers demonstrated correct system functionality and
an acceptable number of hardware issues. There was
good comparability between runs using single samples
under random mode conditions in the RSS test, with
near-perfect correlation for all comparisons and few
deviations which were attributable to precision of assays.
Finally, system practicability determined by user survey
met or exceeded operator expectations. Previous studies
have described the excellent analytical precision of assays
used on the cobas t 711 and cobas t 511 analyzers
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Table 2 Comparison of technical accuracy assessed by correlation and regression coefficients for samples run on the cobas t 711 (three
study sites) and cobas t 511 (one study site) analyzers for each assay
Correlation (Pearson’s r) Slope (Passing–Bablok) Intercept
Assay cobas t 711a cobas t 511b cobas t 711a cobas t 511b cobas t 711a cobas t 511b
aPTT 0.992–1.000 0.980 0.951–0.987 0.937 0.132–0.337 0.444
aPTT Lupus 0.997–1.000 0.998 0.950–1.002 0.980 0.100–1.21 0.052
aPTT Screen 0.998–0.999 0.999 0.985–1.005 1.000 0.286–0.454 0.000
D-Dimer 1.000–1.000 1.000 0.992–1.000 1.002 0.00642–0.00799 0.00145
Fibrinogenc 0.994–0.999 NR 1.006–1.032 NR 12.1–0.0774 NR
PT-derived Fibrinogen 0.995–0.999 0.998 0.987–1.000 0.993 2.00–2.75 0.0987
PT Owren 0.999–1.000 1.000 1.000–1.004 1.000 0.0500–0.0133 0.100
PT Rec 1.000–1.000 1.000 0.991–1.000 0.988 0.000–0.0313 0.0702
Thrombin Time 0.967–0.997 0.952 0.968–1.023 1.040 0.476–0.252 1.18
Reference standard was that of routine machine used in each laboratory and acceptability criteria for each assay are shown in Table S1, http://links.lww.com/BCF/A72.
aPTT, activated partial thromboplastin time; NR, none reported; PT, prothrombin time; Rec, recombinant human thromboplastin reagent. a cobas t 711 analyzer tested at
three sites (except Fibrinogen, two sites). b cobas t 511 analyzer tested at one site. c Comparison not performed on cobas t 511 analyzer.
compared with existing commercially available methods
[26,27,29]. Our results complement and build on these
previous data by further demonstrating consistency in
analytical performance with the two analyzers and
user satisfaction.
Our results demonstrated equivalence between the cobas
t 711 and cobas t 511 platforms. This was to be expected,
as both systems are built from functionally identical
components and implement identical assay processes
using the same reagents and disposables. The platforms
differ only with respect to throughput. The cobas t 711 –
a high-throughput analyzer capable of running a maxi-
mum of 390 tests/h according to manufacturer specifica-
tions – had a calculated maximum throughput for the
equivalent scenario in our study (PT/aPTT only) of 396
tests/h at one site, and an average throughput of 303–340
tests/h in routine-like conditions across assays and sites.
In comparison, the cobas t 511 – a mid-throughput
analyzer capable of running a maximum 195 tests/h –
had an average throughput of 124 tests/h in routine-like
conditions. These results compare favorably with data
describing other high-throughput automated analyzers
[33–35], and offer potential benefits in terms of increased
efficiency and capacity in laboratories.
Of particular note in this study, the high reagent loading
capacity with the cobas t 711 analyzer resulting in less
frequent reagent top-up required, coupled with the auto-
matic reagent reconstitution, means a reduced technician
daily workload and increased laboratory efficiency. In
addition, the potential walkaway time of several hours
seen with the cobas t 711 analyzer will be of benefit for all
laboratories with regards to resource management and
increasing efficiency.
The current analyses were conducted in a simulated
real-world, routine setting to test instrument perfor-
mance under stress, beyond the clinical conditions for
precision testing in CLSI guidelines. In addition, the
sites selected for this study represent high-workload
core laboratories for large teaching hospitals. These
settings are high case-load with broad patient popula-
tions across emergency medicine and chronic care
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settings, offering good external validity to these data in
the real world. One limitation of this study that should
be considered when interpreting the results is the lack
of comprehensive standardized method comparison
with another device. As this study was only conducted
to determine system behavior of the two analyzers in a
real-world setting, no conclusions can be made regard-
ing superiority or inferiority to other available laboratory
methods; further studies may be warranted in this
instance. In addition, while not a limitation of this study
design, current data describe only the analytic perfor-
mance of the analyzers and not their clinical perfor-
mance (e.g. ability to detect coagulation factor
abnormalities).
Conclusion
In conclusion, this multicenter study confirmed the ana-
lytical performance, functionality and reliability of the
cobas t 711 and cobas t 511 analyzers when used in
simulated routine laboratory conditions. Both analyzers
are suitable for the accurate and reliable measurement of
coagulation parameters in routine clinical practice and
offer high-workload core laboratories options and advan-
tages over existing methodologies.
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